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Abstract: This is a crucial transition time for human
genetics in general, and for HIV host genetics in particular.
After years of equivocal results from candidate gene
analyses, several genome-wide association studies have
been published that looked at plasma viral load or disease
progression. Results from other studies that used various
large-scale approaches (siRNA screens, transcriptome or
proteome analysis, comparative genomics) have also shed
new light on retroviral pathogenesis. However, most of
the inter-individual variability in response to HIV-1
infection remains to be explained: genome resequencing
and systems biology approaches are now required to
progress toward a better understanding of the complex
interactions between HIV-1 and its human host.
Introduction
Many fundamental questions about how and why humans differ
in their susceptibility to HIV-1 remain largely unanswered. For
example, it has long been known that a fraction of the human
population cannot be infected by HIV-1 [1,2]. We still do not
know, however, whether most of those who are resistant to
infection are resistant due to innate or adaptive immunity, or to
some other mechanism. Nor are the precise pathways that allow
apparently permanent control of the virus amongst a subset of
those that do become infected well understood. These questions
are obviously central in the effort to develop effective strategies to
combat HIV-1, and at their heart, they are genetic.
Until recently, our capacity to systematically address these issues
was limited. But genomic analyses have advanced to the point that
comprehensive or nearly comprehensive analyses of the role of
genetic variation in viral control is now within reach. A series of
genome-wide association studies has already provided a detailed
description of how common variation influences control of HIV-1
[3–9]. More importantly, next-generation sequencing is now
sufficiently advanced such that a dedicated effort to uncover the
role of rare variation has become feasible. Coupling these new
developments with rich cohorts being built under the auspices of
international groupings such as the Center for HIV/AIDS
Vaccine Immunology (CHAVI) and the International HIV
Controllers Study, all ingredients are now available for drawing
conclusive answers to these fundamental questions.
Here, we first review what is known about how genetic variation
influences HIV-1 acquisition and control. We then describe new
developments and argue that a concerted effort is now appropriate
to bring these elements together to answer these outstanding
questions decisively and draw the appropriate lessons for vaccine
development as well as understanding of pathogenesis.
Cohorts
Cohorts for the Study of HIV-1 Acquisition
In various high-risk populations, there are reports of individuals
that have been repeatedly exposed to HIV-1 and yet have not
been infected. Exposure itself has been assessed in various ways,
but in all cases it appears that portions of the population are
protected. Perhaps the most striking example is the case of
hemophilia: a vast majority of severe hemophilia A patients born
before 1979 became HIV-1 seropositive, due to virtually universal
exposure to contaminated batches of factor VIII concentrates.
Still, about 5% of them remained seronegative [1]. Other
examples of exceptional resistance to infection have been
described in cohorts of men who have sex with men reporting
high-risk behavior [10] and of female sex workers in Nairobi,
Kenya [11]. Finally, virtually all infectious disease clinicians report
individual patients with very high levels of exposure that did not
become seropositive; a celebrity such as Sir Elton John also
described himself as a lucky person that mysteriously avoided
infection. The genetic analysis of well-characterized highly
exposed, yet uninfected, individuals is thus essential. An alternative
approach to study HIV-1 acquisition is to test for differences in
allelic distribution between patients with HIV-1 and large cohorts
of presumably uninfected controls, since the infected population
will then be depleted in protective factors or enriched in alleles
conferring enhanced susceptibility to infection. Many groups
active in HIV-1 host genetics research have recently created the
International HIV Acquisition Consortium to initiate such a study.
Cohorts for the Study of Viral Control
The existence of clinical cohorts/studies prospectively collecting
data and samples from individuals with HIV makes it more
straightforward to study post-infection outcomes. Various mea-
sures of HIV-1 control and disease progression have been used as
phenotypes in host genetic studies (Box 1). Plasma viral load and
CD4+ T cell count are routinely collected during clinical follow-up
and are thus widely available for large numbers of patients. These
markers have been shown to be independent predictors of
progression to severe immunodeficiency [12]. Later measures of
progression like AIDS-defining events, specific opportunistic
infections, or AIDS-related death are more likely to result from
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complex interactions between multiple genetic and environmental
factors: the power to detect true genetic effects is thus reduced. In
addition, later outcomes can only be assessed in historical cohorts,
thanks to the efficacy of current antiretroviral treatments. The study
of the earliest stages of infection represents an especially challenging
task, since identification and recruitment of acutely infected patients
is hampered by significant scientific and sociologic limitations.
Finally, it is important to note that, so far, the vast majority of HIV-
1 host genetic studies focused on patients of Western European
ancestry, in striking contrast with the global distribution of HIV-1
burden. The creation and analysis of cohorts in other ethnic groups
is clearly a priority for ethical reasons, but also because population
diversity increases the likelihood of genetic discovery.
Cohorts for the Study of Therapeutic Outcomes
Human genomic approaches can also be used to study
therapeutic intervention outcomes. Although antiretroviral therapy
is highly effective, critical questions remain about how patients
respond to treatment: genetic variation among individuals and
populations may cause considerable variability in drug pharmaco-
kinetics and pharmacodynamics. In particular, since anti-HIV
medicines are used for life, even modest differences in susceptibilities
to adverse events can become important. Identification of risk
profiles could allow the tailoring of the drugs to minimize the long-
term toxicities associated with treatment, like metabolic disturbanc-
es and cardiovascular diseases. Consequently, an important effort
should be made to obtain informed consent for genetic testing from
participants in randomized clinical trials, which represent an ideal
setting for pharmacogenetic discovery, as recently demonstrated, for
example, in hepatitis C research [13,14]. Genetic variation will also
be responsible for differences in vaccine immunogenicity and
tolerability, and as such needs to be considered in the design and
evaluation of current and future HIV-1 vaccine trials.
Common Variation and the Control of HIV-1
Most recent HIV-1 host genetic studies have interrogated
human genetic variants for their association with viral load (either
as a continuous trait, or as a categorical variable in studies of
controllers) and CD4+ T cell decrease. Only a few confirmed
genetic associations are understood in terms of the responsible
causal sites, and even if it is the case, fundamental questions
remain about the exact mechanisms involved in viral control. Most
prominent is the example of human leukocyte antigen (HLA) class
I variation, and notably of HLA-B*5701, whose protective effect
has been shown to be the largest contributor to inter-individual
variability for both viral set point and CD4+ T cell decline in
genome-wide association studies performed in populations of
recent European ancestry [3–7]. Interestingly, a very similar result
has also been observed in a genome-wide study performed in
African-Americans, where HLA-B*5703 was the most important
determinant of viral control [9]. HLA-A, -B and -C are extremely
polymorphic and encode protein products that are fundamental in
the immune recognition process: expressed at the cell surface, they
present antigenic epitopes including processed viral peptides to
CD8+ T lymphocytes, thereby initiating a cytotoxic T cell (CTL)
response. Other HLA-B types have been shown to associate with
differences in HIV-1 outcomes [15]: HIV-1 control is better in the
presence of HLA-B*27, B*51, and B*5801, but poorer in the
presence of HLA-B*5802 and of alleles from the HLA-B35Px
group [16–19]. Homozygosity for class I alleles also leads to faster
progression and higher viremia, presumably because it reduces the
diversity of the epitope recognition machinery, thereby impairing
antiretroviral CTL response [16].
Beyond the key role they play in the induction of CTL responses,
HLA class I molecules are also ligands for the killer cell
immunoglobulin-like receptors (KIRs), expressed at the surface of
natural killer (NK) cells. KIRs regulate NK cell activation status
through inhibitory or activating signaling and can thereby have a
direct modulating effect on the innate immune response to HIV-1
infection. Certain combinations of KIR genes andHLA class I alleles
have epistatic influences on the outcome of HIV-1 infection [20]:
KIR3DL1 and KIR3DS1 have been associated with better control of
HIV-1 when they are found in patients that have HLA-B alleles with
a Bw4 specificity. Recently, we showed that copy number variation
of the KIR3DL1/KIR3DS1 locus results in differences in HIV-1
control in the presence of HLA-Bw4 (K. Pelak, A. C. Need, J. Fellay,
K. V. Shianna, S. Feng et al., unpublished data).
Other genetic associations, albeit statistically unequivocal, are still
poorly understood. A polymorphism located in the upstream region
of HLA-C (HLA-C -35) associates with both HIV-1 control and
expression levels of the gene [3,21], suggesting that the number of
HLA-C molecules expressed at the cell surface might play a role in
the efficacy of the immune response. Genome-wide studies also
detected additional independent associations in the major histo-
compatibility complex (MHC) [3–5,7], but the long-range linkage
disequilibrium structure of the region makes it virtually impossible
to pinpoint the real causal sites using genetic data alone.
Outside of the MHC, nearly all genetics findings reported to
date resulted from candidate gene studies. As a consequence,
variants were identified in genes implicated in HIV-1 life cycle or
in immune-related genes. The problem, however, is that most
results are equivocal or controversial, due to technical or
methodological limitations. In particular, the quasi-systematic
absence of correction for population stratification before the
genome-wide era has been responsible for a high number of false
positive results [7,22]. In fact, other than HLA and KIR variation,
only polymorphisms located in the chemokine receptor cluster on
chromosome 3 have been repeatedly associated with HIV-1
control: specifically, heterozygosity for a 32–base pair deletion in
CCR5 (CCR5D32), variants of the CCR5 promoter region, and a
non-synonymous coding change in CCR2 (V64I) have been
consistently shown to associate with differences in viral load
and/or disease progression [7,23–28].
Common Variation and Acquisition
Variation in CCR5 remains the only human genetic determinant
that has been proven to significantly impact HIV-1 acquisition:
Box 1. Phenotypes That Have Been Used in
Genetic Studies of HIV-1 Infection
HIV resistance/acquisition:
N Mucosal exposure
N Intravenous exposure
N Mother-to-child transmission
HIV viral load:
N Set point viral load
N Intracellular HIV-1 DNA level
N Viral control (elite control/viremic control)
HIV disease progression:
N Slope of CD4+ T cell decrease
N Time to CD4+ T cell decrease below a certain threshold
N Time to AIDS 1987/AIDS 1993
N Time to death
N Long-term non-progression
N Rapid disease progression
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both the CCR5D32 variant (present in homozygous form in about
1% of Europeans) and the m303T.A point mutation (much rarer)
result in a defective CCR5 protein product that is not expressed at
the cell surface [23,29–31]. When present in homozygous or
combined heterozygous form, they confer complete resistance to
infection by HIV-1 viruses that use CCR5 as co-receptor. Of note,
those individuals remain susceptible to infection by CXCR4-using
viruses (including dual-tropic viruses) that associate with more
rapid HIV disease progression [32].
Other gene variants were reported to protect against acquisition
or to increase susceptibility to infection, but they are at best
supported by weak evidence from candidate gene studies. In fact,
none could yet be replicated using contemporary standards widely
accepted in human genetics, notably a correction for population
stratification: for example, we and others reported a lack of
association between HIV-1 susceptibility and the number of copies
of CCL3L1 [33–35], or the allelic distribution of a DARC promoter
variant [36–40].
Given the importance of the natural model of resistance to
HIV-1 infection, it comes as a surprise that no genome-wide study
has been published that looks at correlates of protection. It is
clearly a priority for the HIV genetic field to carry out such
studies.
The Role of Genetic Variation: The Complete
Picture
It seems reasonable to conclude that most of the common
variants important in the control of HIV-1 have now been
identified, at least in individuals of European ancestry. Despite
this, it appears that most of the inter-individual differences in
control remain to be explained. The confirmed host genetic
determinants of HIV-1 control are only able to explain about 20%
of the observed variation in viral load or disease progression [7]. It
is noteworthy that such limited genetic knowledge can already be
used to refine the prediction of disease progression, beyond the
information provided by viral load only, as shown in Figure 1.
So, what is responsible for the large variability in HIV-1
control that still remains unexplained? Clearly, part of it is
attributable to the virus itself, as demonstrated by sudden changes
in disease course and/or viral set point upon super-infection in
chronically infected patients [41] and by sizeable differences in
viral load set point that can be observed between the donor and
the recipient in HIV-1 transmission pairs [42]. Environmental
influences also play a role: for example, pro-inflammatory
diseases are often associated with a significant increase in HIV-
1 viral load, while co-infections with viruses like GB virus C,
Figure 1. An additive genetic score helps predict HIV-1 disease progression. Data are from Fellay et al. [7]: 1,071 individuals of Caucasian
ancestry with HIV-1 are included in the analysis. The columns show the proportions of individuals that reached a progression outcome (CD4+ T cells
,350/ul or initiation of combined antiretroviral treatment with CD4+ T cells ,500/ul) during the first 5 years after estimated date of seroconversion
in categories defined by HIV-1 viral load and by a simple additive genetic score, in which one unit is counted for each ‘‘protective’’ allele. The
minimum score is 0 for individuals that are homozygous for the major allele at rs2395029 (a proxy for HLA-B*5701), rs9264942 (HLA-C -35 variant),
rs9261174 (ZNRD1), and CCR5-D32. The maximal observed score is 3 since no individual was heterozygous or homozygous for the minor allele at all
four sites. Individuals were grouped in three categories to clearly show that the genetic score refines the prediction of progression, beyond the
information provided by viral load only, throughout the range of set point values.
doi:10.1371/journal.ppat.1001033.g001
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HTLV-1, and HIV-2 have been reported to have an inhibitory
effect on HIV-1 replication [43].
However, as it is the case for many other human complex traits,
it is not unreasonable to assume that rarer genetic variants are
responsible for a sizeable fraction of the unexplained inter-
individual differences [44]. For example, it is clear that a fraction
of the population is highly resistant to infection by HIV-1. While
homozygosity for CCR5D32 is responsible for some of these cases
[23,29,30], it appears to explain only a minority of such
observations. Several studies have shown a higher frequency of
CCR5D32/D32 in HIV-uninfected hemophiliacs than in the
general population (up to 25% compared to 1%, respectively),
with the highest frequencies in those with severe hemophilia [45–
47]. Homozygosity for CCR5D32 is also significantly enriched in
highly exposed, yet seronegative homosexual men [23,24]. While
those numbers clearly illustrate the high degree of exposure in
these populations, it also suggests that other protective mecha-
nisms are responsible for most individual cases of resistance. So
far, genome-wide studies in these groups also fail to reveal any
strong common variants conferring further protection (D. Gold-
stein, unpublished data). The identification of the other variants
responsible for protection therefore will require a deeper
interrogation of the human genome than is possible using
genome-wide association studies.
While still expensive and difficult to implement due to
computational and bioinformatic challenges, it is feasible to carry
out systematic discovery genetics using whole exome or whole
genome sequencing [48]. Several recent reports demonstrated that
the cause of Mendelian diseases can be identified using such
resequencing strategies [49–51]. In the HIV field, one project
already underway involves sequencing the complete genomes of 50
hemophilia patients (Figure 2). Discovery of variants in this
framework will depend principally on three factors: 1) the initial
population frequency, 2) the degree of enrichment in frequency in
the exposed uninfected individuals, and 3) the defining character-
istics of a rare causal variant, e.g., predicted functional
Figure 2. Project framework: human genome resequencing of hemophilia A individuals exposed to HIV-contaminated factor VIII in
1979–1984, yet uninfected.
doi:10.1371/journal.ppat.1001033.g002
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consequence, clustering in a gene/pathway, conservation. What-
ever the ease of recognition, it seems reasonable to expect that
causal variants can be identified using a combination of
sequencing in a discovery cohort and confirmation by genotyping
in a much larger validation cohort.
Other phenotypes related to HIV control that could be studied
using a similar design include extremely rapid versus extremely
slow progression, as well as resistance to infection through mucosal
exposure. Other more complicated phenotypes may also be
interesting targets for study, such as the occurrence of persistently
high viral loads without progression to AIDS [52], extreme levels
of microbial translocation during acute infection [53], or unusual
immune activation patterns (Box 2).
Systems Approach
Beyond the information generated by genome studies, the field can
now press ahead with novel approaches that use a range of
technologies. Prominent among these are the analyses of the
transcriptome and proteome, and small interfering RNA (siRNA)
screens (Figure 3). These genome-wide studies generate large data sets
that can be analyzed in isolation, and, increasingly, in an integrated
manner [54,55]. Below we summarize key studies in the HIV field
using these techniques, and the first efforts at feeding information
across studies. The last section will address the prospects for a systems
biology approach in the study of HIV-1 biology and pathogenesis.
Transcriptome Analyses
New microarray technologies have recently allowed the genome-
wide analysis (.<20,000 transcripts) of infected cells in vitro, and in
vivo in individuals with HIV [56–59]. Dynamic analyses have been
also completed in animal models. The cell types investigated varied
from the collective study of peripheral blood mononuclear cells, to
cell type–specific studies [60]. The overarching messages from these
studies are (i) the massive modulation of the antiviral defense systems
(the interferon response, including the antiretroviral intrinsic
cellular defense apparatus), (ii) the prominent modulation of genes
involved in the cell cycle and degradation/proteasome pathways,
and (iii) the absence of a characteristic expression pattern of effective
control of viral replication (e.g., in elite controllers). Evidence of a
persistent deregulated interferon response upon infection is of
particular interest in light of comparative studies of pathogenic and
non-pathogenic animal models [61,62]. Upon primary simian
immunodeficiency virus infection of sooty mangabeys and of
African green monkeys, these natural hosts display a strong
interferon response at seroconversion followed by distinctive
down-regulation despite persistence of ongoing active viral
replication [63,64]. The precision of transcriptome analyses will
be greatly improved through the added resolution of RNA-Seq [65]
and the capacity to look at the transcriptome in single cells [66].
Proteome Analyses
Large-scale studies are limited by the number of proteins that
can be assessed in a quantitative fashion. Analyses of 2,000 to
3,200 proteins identified 15%–21% to be differentially expressed
upon infection [67,68], including changes in the abundance of
proteins with known interactions with HIV-1 viral proteins. The
NCBI HIV-1 Human Protein Interaction Database (http://www.
ncbi.nlm.nih.gov/RefSeq/HIVInteractions/) summarizes over
3,000 interactions with almost 1,500 human genes [69]. Other
datasets of interest include the human–pathogen protein–protein
interactions (PPIs)/pathogen interaction gateway (PIG) [70] that
reports that pathogens tend to interact with hubs (proteins with
many interacting partners) and bottlenecks (proteins that are
central to many paths in the network) in the human PPI network
[71]. No integrated approaches have been used so far to analyze
these data in the context of other genome-wide studies.
siRNA and Gain-of-Function Screens
Three siRNA transfection [72–74] and one short hairpin RNA
(shRNA) [75] transduction studies have targeted the coding RNA
for .20,000 human proteins. Approximately 1,000 proteins have
been identified as potentially necessary for an optimal viral
replication. However, there was minimal overlap across studies—
possibly because of differences in cell types and in study design.
None of the studies captured or were designed to identify genes
that would restrict viral replication—i.e., their silencing would
result in greater viral production. Overall, 34 genes were identified
in two or more of the transfection screens. However, among those
genes that were shared by one or more studies, a pattern emerged
that involves the nuclear pore machinery, the mediator complex, a
number of key kinases, and components of the NF-kB complex
(Figure 4). One gain-of-function screen used a cDNA library
representing 15,000 unique genes in an infectious HIV-1 system
[76]. This led to the proposal of novel proviral host factors.
Evolutionary Data
Genes involved in immunity and inflammation among those
exhibiting the strongest signatures of positive selection both across
species and within humans [77–84]. Increasingly, evolutionary
and comparative sequence analyses across species or within
human populations can be used to identify genes that have played
a major role in host survival and are therefore likely to influence
modern susceptibility to, or pathogenesis of, infectious diseases
[78,85–87]. Given the relevance of endogenous and exogenous
retroviruses in primate evolution, the identification of genomic
signatures can provide an additional layer of data for analysis of
contemporary susceptibility to HIV-1. A number of targeted
analyses of genes involved in cellular defense against retroviruses
have been reported [88–92]. A systematic study of long-acting
selective pressures on primate genomes (analysis of 140 genes
proven or possibly involved in HIV-1 biology and pathogenesis)
reached the following conclusions: (i) there are three general
groups of genes presenting different evolutionary histories of their
coding regions in primates, (ii) analyses allow a non a priori
identification of candidate residues that affect host–pathogen
interactions, and (iii) a subset of genes may remain under positive
selective pressure in modern human populations [92].
Data Integration
Progressively, researchers aim at integrating different layers of
data. Rotger et al. [59] examined the correspondence of results from
genome-wide transcriptome analysis of differentially expressed
mRNA in CD4 T cells from infected individuals with results from
Box 2. Examples of Target Phenotypes for
Human Genome Resequencing Studies
N Resistance to HIV-1 infection in highly exposed uninfected
individuals
N Very rapid disease progression
N Elite viral control
N Poor viral control in HLA-B*57 individuals
N Persistently high viral loads without apparent disease
progression
N Degree of intestinal microbial translocation during acute
infection
N Unusual immune activation patterns
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analysis of cis-acting genetic variants modulating gene expression in
the same samples. In this work, 265 genes were differentially
expressed in CD4 T cells across the range of viral set point, and 160
genes were shown to have cis-acting genetic variants associated with
expression. However, the overlap between the two lists was minimal:
only one gene was common to both lists: OAS1, an interferon-
stimulated gene. However, SNPs in this gene are not associated with
notable differences in viral set point or disease progression.
Bushman and colleagues [54] applied meta-analytical proce-
dures to assess a wider range of genome-wide studies and public
interaction databases. A higher level of signal would be obtained if
the data were evaluated in the frame of specific networks and
cellular systems. The approach led to the identification of at least
11 densely connected clusters. These clusters, which are enriched
for proteins identified in multiple separate screens, specify cellular
subsystems associated with HIV replication: the proteasome,
subunits of RNA polymerase II and associated factors, the
mediator complex, the Tat activation machinery, RNA binding
and splicing proteins, and the BiP/GRP78/HSPA5 and CCT
chaperones. The study went one additional step to organize data
Figure 3. Genome-wide and large-scale studies published since 2007 in the HIV field. The number of studies is in parentheses. Diverse sets
of results and data are compiled in an encyclopedia of overlaps between studies (http://www.hostpathogen.org/). This approach serves to identify
networks used by HIV-1 to support its replication. Figure updated from reference [55] (http://F1000.com/Reports/Biology/content/1/71).
doi:10.1371/journal.ppat.1001033.g003
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in an ‘‘encyclopedia’’ of host factors assisting HIV replication
(http://www.hostpathogen.org/).
There is growing interest in applying non-reductionist ap-
proaches such as systems biology to the study of infectious diseases.
The general premise of systems biology includes the high-
throughput quantitative approach to a biological system that can
be subjected to iterative cycles of perturbation, and the modeling
of the collected data. HIV infection, which results in a perturbed
environment that can be exogenously manipulated through
treatment, or modulated by genetic determinants, should now be
approached under this research paradigm.
Conclusion
The aim of HIV host genetic research is to comprehensively
describe human genetic influences on HIV/AIDS. Some genetic
factors have now been convincingly associated with viral control or
resistance to infection, yet much effort is still needed to get the full
picture. The field is now moving simultaneously towards greater
depth in genome analysis and towards more breath and
integration through systems biology. This ongoing transition
brings renewed hopes that genetic analysis of the human host
will contribute substantially to understanding HIV-1 pathogenesis
and developing new strategies to stamp out the AIDS pandemic.
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